CX3CR1 identifies PD-1 therapy–responsive CD8(+) T cells that withstand chemotherapy during cancer chemoimmunotherapy

Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti–PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for t...

全面介紹

Na minha lista:
書目詳細資料
發表在:JCI Insight
Main Authors: Yan, Yiyi, Cao, Siyu, Liu, Xin, Harrington, Susan M., Bindeman, Wendy E., Adjei, Alex A., Jang, Jin Sung, Jen, Jin, Li, Ying, Chanana, Pritha, Mansfield, Aaron S., Park, Sean S., Markovic, Svetomir N., Dronca, Roxana S., Dong, Haidong
格式: Artigo
語言:Inglês
出版: American Society for Clinical Investigation 2018
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931117/
https://ncbi.nlm.nih.gov/pubmed/29669928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.97828
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍